RxDoctor Payments Data

Rocco Arcieri, MD

Family Medicine · Dallastown, PANPI 1447221536

Payments from drug & device makers

$1,344in general payments, 2019–2025

Across 91 payments — averaging $14.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$276
  • Johnson & Johnson$182
  • Abbott$166
  • GSK$162
  • Biofire Diagnostics, LLC$75
  • Novartis$62
  • plus $420 from 15 others

What the payments were for

  • Food & beverage$1,344100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,344 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$184,579
Medicare patients
194
Services billed
8,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$126,893
OzempicSemaglutide21$40,528
JardianceEmpagliflozin30$36,373
XareltoRivaroxaban20$32,779
TrulicityDulaglutide14$23,296
FarxigaDapagliflozin Propanediol26$17,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,409
JanuviaSitagliptin Phosphate11$15,263
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$15,141
EntrestoSacubitril/Valsartan14$13,494
Bosentan12$9,032
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$8,797
VeozahFezolinetant12$6,642
Novolog FlexpenInsulin Aspart20$6,089
Risedronate Sodium34$4,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$276$126,893124 claims
Novo NordiskOzempic$52$40,52821 claims
Johnson & JohnsonXarelto$182$32,77920 claims
Lilly USA, LLCTrulicity$30$23,29614 claims
GSKTrelegy Ellipta, Arexvy$162$18,91833 claims
AstraZenecaFarxiga$12$17,99526 claims
NovartisEntresto$62$13,49414 claims
Astellas Pharma US IncVeozah$28$6,64212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dallastown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →